Publications by authors named "Eliseo Pastor-Villalba"

Objective: Hepatitis B (HB) is a preventable disease and a public health challenge due to its high morbidity and mortality. This study was conducted within the framework of the World Health Organization's strategy, which includes establishing prophylactic measures to prevent vertical transmission. The aim was to assess the degree of implementation of HB preventive measures to avoid vertical transmission in newborns in Spain.

View Article and Find Full Text PDF
Article Synopsis
  • This study evaluates nirsevimab, a monoclonal antibody, for preventing respiratory syncytial virus (RSV) infections in infants under ten months in Spain.
  • It involved a large immunization campaign where infants born after April 1, 2023, received nirsevimab either at birth or through a catch-up program.
  • Results showed nirsevimab had an overall effectiveness of 75.8% and 80.2% in the catch-up group, highlighting its role in reducing RSV-related illnesses in primary care settings.
View Article and Find Full Text PDF

Public funding of vaccines may enhance vaccination rates, co-administration, and timeliness. The impacts of including the serogroup B meningococcus vaccine (MenB) into the national immunisation schedule on vaccination rates, co-administration rates, and timeliness were assessed using a population-based pre-funding (2022) and post-funding (2023) study design. MenB vaccination rates improved after funding and were in line with previously funded vaccines.

View Article and Find Full Text PDF
Article Synopsis
  • Respiratory syncytial virus (RSV) is a major cause of illness and hospitalization in young children, particularly those under 1 year old.
  • In the Valencian Community of Spain, a new monoclonal antibody called nirsevimab was introduced for high-risk children and those under 6 months as a preventive measure for the 2023-2024 RSV season.
  • Preliminary results indicate that the immunization campaign achieved 88.5% coverage, with immunized children showing a threefold reduction in RSV incidence and lower hospitalization rates for respiratory infections compared to those who were not immunized.
View Article and Find Full Text PDF
Article Synopsis
  • * This effectiveness was validated through two different research methods (screening and test-negative) in a multicenter study across nine hospitals in three regions.
  • * The antibody did not provide any protection against hospitalizations for lower respiratory tract infections caused by viruses other than RSV, and these findings could help influence public health policies.
View Article and Find Full Text PDF

Influenza vaccination in pregnant women shows a clear benefit/risk ratio. Influenza vaccines are currently being developed using new platforms. It is essential to analyse the safety of these new vaccines in this population group, underrepresented in clinical trials.

View Article and Find Full Text PDF

Vaccine safety surveillance is essential in vaccination programs. We accomplished a descriptive study of surveillance AEFI-reporting rate in human papillomavirus (HPV) vaccine administered in the Valencian Community, Spain. Data were obtained from Spanish Pharmacovigilance Adverse Reactions Data (FEDRA).

View Article and Find Full Text PDF

Eliminating measles and rubella and preventing congenital rubella infection plan of WHO highlighted the need to assess vaccination coverage and develop strategies to improve it and eliminate pockets of low immunization coverage. It exists evidence about the potential role of immunization information systems to improve coverage. The aim of this article is to describe the actions taken from the Vaccine Information System of Valencian Community addressed to improve the vaccination coverage.

View Article and Find Full Text PDF

The process of introducing the human papillomavirus (HPV) vaccine aimed at teenage girls has not been entirely without controversy in Spain. This vaccine was originally hyped as a preventive measure in the fight against cervical cancer but the resulting euphoria was tempered by a message calling for evidence. During administration of the second dose of the vaccine in February 2009, an unexpected turn of events attracted vast media coverage when two teenagers experienced adverse effects after immunization in Valencia (Spain).

View Article and Find Full Text PDF

Background: The loss of confidence in the safety of vaccines derived from alarm conditions, as in the case of the flu pandemic may affect both vaccination coverage and the sensitivity to the reporting of suspected adverse reactions associated vaccines (SRAAV). The aim of the study is to describe the adverse effects reported to the vaccine against pandemic influenza in the 2009-2010 season and against seasonal influenza in 2009-2010 and 2010-2011 seasons, by type of vaccine, risk groups and by age group in the Valencian Community (CV).

Methods: A retrospective descriptive study has been made of the individuals presenting suspected adverse reactions to the influenza vaccine reported through the Vaccine Information System during the seasons 2009-2010 and 2010-2011 in the Valencian Community.

View Article and Find Full Text PDF

Background: Heptavalent pneumococcal conjugate vaccine (PCV-7) was licensed to provide immunity against pneumococcal disease caused by seven serotypes of S. pneumoniae. Thirteen-valent pneumococcal conjugate vaccine (PCV-13) includes 6 additional serotypes for preventing invasive pneumococcal disease.

View Article and Find Full Text PDF

Background: In the context of the policies of rational use of medicine, and in order to achieve an efficient management of the vaccinations programs, we expect to know the number of packings and cost of prescribed vaccines not included in the vaccination programs of Valencian Community and its departments during 2009 and to analyze its evolution since 2004, focusing on an analysis of Heptavalent pneumococcal conjugate vaccine in children under two years old.

Methods: Retrospective descriptive study to analyze the prescriptions of vaccines in Valencian Community during 2009 and its evolution since 2004.

Variables: vaccine availability, number of packings, group of beneficiary (actives/pensioners), department, and cost of prescriptions.

View Article and Find Full Text PDF

Feline aggression towards people has a smaller incidence than canine aggression, but also represents an important public health problem. The aim of this work was to analyse feline aggression reported towards people, to estimate its incidence and to assess the risk factors involved. The information was obtained from the Public Health Centres in the Valencian Region (Spain).

View Article and Find Full Text PDF

Background: Pneumococcal pneumonias comprise a major health problem. This study is aimed at ascertaining the evolution of pneumococcal pneumonias in hospital settings within the Autonomous Community of Valencia throughout the 1995-2001 period.

Methods: The cases of pneumococcal pneumonias were selected from the Minimum Basic Data Set.

View Article and Find Full Text PDF